No Evidence That Creatine Supplementation Promotes Cancer Growth in Humans
Current evidence does not support the claim that creatine supplementation accelerates tumor growth in humans, and recent data suggest it may actually have anti-cancer effects. While one preclinical study raised concerns about metastasis promotion, this finding has not been replicated in human populations, and emerging research points in the opposite direction.
The Evidence Landscape
Preclinical Concerns vs. Human Data
The concern about creatine and cancer stems primarily from a 2026 mouse study 1 showing that exogenous creatine supplementation promoted tumor metastasis through platelet activation mechanisms. However, this animal model finding has not translated to human cancer risk. In fact, a large population-based study using NHANES data from 2007-2018 with 25,879 American adults found the opposite: for each standard deviation increase in dietary creatine intake, cancer risk decreased by 5% 2. This inverse association was strongest in males and overweight individuals, with particularly significant protection in older adults (14% risk reduction).
Safety Profile in Clinical Guidelines
Multiple authoritative guidelines address creatine supplementation without cancer warnings:
The 2021 UEFA Expert Group statement 3 explicitly states creatine has "no negative health effects following appropriate protocols" when used at standard doses (loading: 20g/day for 5-7 days; maintenance: 3-5g/day)
The 2010 Duchenne Muscular Dystrophy guidelines 4 note that an RCT of creatine in DMD failed to show clear benefit, but the only safety concern mentioned was renal dysfunction in patients with pre-existing kidney disease—no cancer risk was identified
The 2020 ASCO Cancer Cachexia guidelines 5 reviewed creatine supplementation in 263 cancer patients and found it did not improve outcomes, but reported no safety concerns or tumor progression
Mechanistic Complexity
Recent research reveals creatine's dual nature in cancer biology 6:
Anti-tumor effects:
- A 2025 study 7 demonstrated that creatine actually induces ferroptosis (programmed cell death) in colorectal cancer through SLC6A8-mediated uptake
- Creatine supplementation suppressed tumor growth, enhanced CD8+ T cell infiltration, and sensitized tumors to anti-PD-1 immunotherapy 7
- The compound may have anti-inflammatory, antioxidant, and immunomodulatory properties 2
Context-dependent concerns:
- The metastasis-promoting effect seen in mice 1, 8 appears specific to certain tumor types and may involve platelet activation mechanisms not necessarily relevant to human supplementation
- A 2020 rat study 9 found no acceleration of tumor growth or increased aggressiveness with creatine supplementation in Walker-256 tumor-bearing animals
Clinical Recommendations
For Patients Without Cancer
Creatine supplementation at standard doses (3-5g/day maintenance) is safe based on decades of use and guideline endorsements 3. The only established precaution is monitoring renal function in patients with pre-existing kidney disease.
For Cancer Patients
Exercise caution but recognize potential benefits:
- The population data suggest protective effects rather than harm 2
- Emerging immunotherapy data show potential synergy with checkpoint inhibitors 7
- However, given the mechanistic complexity and limited human cancer-specific trials, discuss with the oncology team before initiating supplementation
- If a cancer patient has been taking creatine and shows evidence of renal dysfunction, discontinue per standard guidelines 4
Monitoring Parameters
When using creatine (in any population):
- Serum creatinine should be monitored, particularly in those with baseline renal impairment 10, 11, 12, 13
- The 2018 ASCO guidelines 13 recommend monitoring creatinine prior to each dose in patients on nephrotoxic therapies
- No specific cancer surveillance is warranted based on creatine use alone
Key Caveats
The preclinical metastasis data cannot be dismissed entirely but must be contextualized: animal models often fail to predict human outcomes, the platelet activation mechanism may not operate identically in humans, and the population-level human data show the opposite trend. The 2022 review 6 appropriately calls for caution when considering creatine supplementation in cancer patients, but this reflects scientific prudence rather than established harm.
The most recent and highest-quality human evidence 2 from 2024, analyzing over 25,000 individuals, shows an inverse relationship between dietary creatine and cancer risk, directly contradicting the "aids cancer growth" narrative. Until prospective human trials in cancer patients demonstrate otherwise, the preclinical concerns remain hypothetical.